Completed PHASE4 INTERVENTIONAL 2-arm NCT02870933

Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery

The Effect of Transepicardial Augmentation on Transseptal Autologous CD 133+ Bone Marrow Cell Implantation to Myocardial Perfusion in Patient Following Coronary Artery Bypass Grafting

Sponsor: National Cardiovascular Center Harapan Kita Hospital Indonesia

Conditions Coronary Artery Disease

Interventions Transepicardial with Transseptal CD 133+ Implantation

Updated 7 times since 2017 Last updated: Mar 16, 2020 Started: Jan 31, 2016 Primary completion: Apr 30, 2018 Completion: Apr 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02870933, this PHASE4 trial focuses on Coronary Artery Disease and remains completed. Sponsored by National Cardiovascular Center Harapan Kita Hospital Indonesia, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
May 2020 — Jan 2021 [monthly]

Completed PHASE4
Dec 2018 — May 2020 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 2 earlier versions

Jun 2018 — Dec 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cardiovascular Center Harapan Kita Hospital Indonesia

Data source: National Cardiovascular Center Harapan Kita Hospital Indonesia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jakarta, Indonesia